A recent study reveals that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight far faster than those who halt traditional lifestyle programs.
Research printed in a leading health publication points out that while obese people frequently drop about a fifth of their body weight while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People buying these treatments should be cognizant of the danger of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment mass within about a year and a half.
Weighing Therapies
The analysis, which reviewed 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
The team point out that individuals who lose weight through diet and exercise usually see a less rapid weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Nutrition scientists suggest the mode of action of the jabs accounts for the amplified rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making overeating far more likely."
A Chronic Issue?
Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Professionals contend that, given the significant potential of relapse, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who say that the results "emphasize the persistent nature of obesity," akin to managing conditions like diabetes.
Patient Accounts
Individuals who have stopped the jabs explain a intense resurgence of cravings.
"I experienced something that goes on and you become ravenous," said one woman.
This difficulty is worsened if individuals have not developed lasting dietary or behavioural modifications during therapy.
Growing Use
Figures suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is more common among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while these medications are potent agents for weight loss, they are not a permanent fix and maintained weight loss likely depends on integrated behavioural changes.
